| Half-life | 11 hours |
| Clearance Route | hepatic |
| Active Metabolites | none |
| Notes | Metabolized via CYP2C9; avoid with strong CYP2C9 inhibitors. Increased risk of CV events with long-term use. |
Severity: Moderate
Adverse Effects:
Dyspepsia, abdominal pain, edema, hypertension, rare hepatic injury, thrombotic risk
Contraindications:
Sulfonamide allergy, severe hepatic impairment, post-CABG pain
Precautions:
Monitor BP; use with caution in renal impairment and cardiovascular disease